<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:43:50Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/28498" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/28498</identifier><datestamp>2026-09-24T00:52:16Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Wright, Gerard</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Surette, Matthew</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2023-05-03T19:14:32Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2023-05-03T19:14:32Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2023</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/28498</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/17559</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Antibiotics are one of the most important advances in medical science, but &#xd;
today, antibiotic-resistant bacteria threaten this legacy. We risk losing our ability to treat &#xd;
acute infections, perform invasive surgeries, and exploit immunosuppressive therapies like &#xd;
transplantation and cancer chemotherapy. The antibiotics we use today have ancient roots &#xd;
and have been produced by microbial denizens of the soil for millions of years before we &#xd;
adopted them in the 20th century. This history has modern consequences, as strategies to &#xd;
resist these compounds have evolved in concert for millions of years. The result is a vast &#xd;
reservoir of antimicrobial resistance that exists in environmental bacteria, which have the &#xd;
potential to be mobilized into human pathogens and cripple our antibiotic arsenal. Here, I &#xd;
set out to deepen our understanding of the environmental resistome, focusing on the &#xd;
rifamycin antibiotics. These compounds inhibit bacterial RNA polymerase and are &#xd;
frontline agents for treating tuberculosis. Environmental bacteria from the phylum &#xd;
Actinobacteria induce the production of resistance enzymes in response to these &#xd;
compounds. Although mechanistic questions remain, we demonstrate that this induction &#xd;
stems from the inhibition of RNA polymerase by rifamycins. The induction process is &#xd;
known to require a specific DNA motif; here, I identify additional sequences as part of this &#xd;
motif and use this information to map inducible rifamycin resistance across the entire &#xd;
phylum. The most common rifamycin-inducible gene was an uncharacterized family of &#xd;
proteins annotated as DNA helicases. I investigated these proteins and discovered that they &#xd;
bind to RNA polymerase and displace rifamycin antibiotics, a novel mechanism of &#xd;
rifamycin resistance. Lastly, we repurposed this inducible system to develop an assay to &#xd;
screen for novel RNA polymerase inhibitors. From this screen, we identified a rifamycin &#xd;
immune to a common environmental resistance enzyme and a new family of rifamycin &#xd;
antibiotics.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Our antibiotic arsenal consists primarily of metabolites produced by soil microbes, &#xd;
which humanity repurposed into life-saving medicines in the 20th century. As a direct result &#xd;
of the natural origin of antibiotics, resistant bacteria exist in these same environments, &#xd;
independent of human use. Individual genetic determinants from this reservoir can emerge &#xd;
in pathogenic bacteria without warning and render antibiotics ineffective. The aim of this &#xd;
work was to understand how environmental bacteria resist the rifamycin class of &#xd;
antibiotics. Firstly, I investigated the ability of some bacteria to sense the presence of &#xd;
rifamycins, and in response produce proteins to protect themselves. I discovered that this &#xd;
process requires specific DNA sequences nearby resistance genes. Using this DNA &#xd;
sequence as a guide I cataloged resistance genes in thousands of bacterial genomes and&#xd;
discovered a new mechanism of rifamycin resistance. Lastly, I exploited this rifamycin &#xd;
sensing system to discover new antibiotics from soil microbes.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Antibiotic Resistance</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Rifamycins</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">UNDERSTANDING AND OVERCOMING INDUCIBLE RIFAMYCIN  RESISTANCE</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>